𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hereditary hemorrhagic telangiectasia–related epistaxis: innovations in understanding and management

✍ Scribed by Nathan B. Sautter; Timothy L. Smith

Book ID
111995589
Publisher
Wiley (John Wiley & Sons)
Year
2012
Tongue
English
Weight
310 KB
Volume
2
Category
Article
ISSN
2042-6976

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The effect of bevacizumab (Avastin) trea
The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia
✍ Jana Simonds; Frank Miller; Jess Mandel; Terence M. Davidson 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

## Abstract ## Objectives/Hypothesis: Determine the effectiveness of treating epistaxis in hereditary hemorrhagic telangiectasia (HHT) with potassium titanyl phosphate (KTP) laser cautery combined with submucosal injection of 100 mg of bevacizumab. ## Study Design: Retrospective pilot study. ##

Safety of intranasal Bevacizumab (avasti
Safety of intranasal Bevacizumab (avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis
✍ Sonia Chen IV; Tom Karnezis; Terence M. Davidson 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

## Abstract ## Objectives/Hypothesis: Assess for complications of intranasal Bevacizumab application in patients with hereditary hemorrhagic telangiectasia (HHT)‐associated epistaxis. ## Study Design: Retrospective chart review. ## Methods: In 58 patients presenting with recurrent HHT epistaxi

Efficacy of intranasal bevacizumab (Avas
Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis
✍ Tom T. Karnezis; Terence M. Davidson 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

## Abstract ## Objectives/ Hypothesis: Intranasal Bevacizumab is an effective therapy for epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT). ## Study Design: Retrospective chart review. ## Methods: In 32 successive patients presenting with recurrent HHT epistaxis 25–100 mg